MAPT and Alzheimer disease: Because 3xTg-AD mice develop both histological hallmarks of AD, senile plaques composed of Aβ, and NFT of tau protein [29], and considering that bapineuzumab was able to reduce tau levels in the CSF from patients with mild-to-moderate AD [30], the effect of scFv-h3D6 in tau pathology was evaluated.